Novo Nordisk A/S (NYSE:NVO) came up during the show in the context of trade discussions between the US and Europe and ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...

The FTSE 100 tracked about a third of a per cent lower this morning amid with another stack of earnings to digest and a key three days in the US likely to set the tone. The S&P 500 slid 0.3 per cent ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

In their zeal to "Make America Healthy Again," top Trump administration officials depict patients and the doctors who treat ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to ...

The new CVS contract for Wegovy and stepped-up direct-to-patient outreach offer concrete levers to boost U.S. volume as early as Q3, helping to stabilize demand in the face of compounding pharmacy ...

Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...